UPDATE: MLV & Co Raises PT On Keryx Biopharmaceuticals On Additional Auryxia Growth Potential

By: via Benzinga
In a report published Wednesday, MLV & Co analyst George B. Zavoico reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ: KERX), ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.